Edition:
United Kingdom

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

27.25EUR
16 Feb 2018
Change (% chg)

€-0.35 (-1.27%)
Prev Close
€27.60
Open
€27.70
Day's High
€27.70
Day's Low
€27.25
Volume
25,474
Avg. Vol
39,358
52-wk High
€27.70
52-wk Low
€16.89

Select another date:

Thu, Feb 8 2018

BRIEF-Biotest says Tiancheng to enter into domination agreement

* DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG

BRIEF-Biotest: Creat Takeover Of Biotest Closed

* MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest

* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST

BRIEF-Biotest: Trimodulin Concept For Phase III Study Coordinated With The Authorities

* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biotest 9-mth revenue at EUR 377.8 mln

* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017

UPDATE 1-Takeover of plasma firm Biotest by China's Creat hits wall in U.S.

* Biotest shares drop 12 percent to 7-month low (Adds share price, background)

China's Creat suffers setback in Biotest deal on U.S. scrutiny

FRANKFURT Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower.

BRIEF-Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling

* ‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​

Select another date: